Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas

The EGFR gene is one of the most frequently mutated and/or amplified gene both in lung adenocarcinomas (LUAD) and in glioblastomas (GBMs). Although both tumor types depend on the mutation for growth, clinical benefit of EGFR tyrosine kinase inhibitors (TKIs) has only been observed in LUAD patients a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ya, Vallentgoed, Wies R., French, Pim J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316468/
https://www.ncbi.nlm.nih.gov/pubmed/30518123
http://dx.doi.org/10.3390/cancers10120489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316468/
https://www.ncbi.nlm.nih.gov/pubmed/30518123
http://dx.doi.org/10.3390/cancers10120489

Ejemplares similares